187 related articles for article (PubMed ID: 34910334)
1. Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles.
Wang Z; Hood ED; Nong J; Ding J; Marcos-Contreras OA; Glassman PM; Rubey KM; Zaleski M; Espy CL; Gullipali D; Miwa T; Muzykantov VR; Song WC; Myerson JW; Brenner JS
Adv Mater; 2022 Feb; 34(8):e2107070. PubMed ID: 34910334
[TBL] [Abstract][Full Text] [Related]
2. Complement opsonization of nanoparticles: Differences between humans and preclinical species.
Li Y; Wang G; Griffin L; Banda NK; Saba LM; Groman EV; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2021 Oct; 338():548-556. PubMed ID: 34481928
[TBL] [Abstract][Full Text] [Related]
3. C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.
Tavano R; Gabrielli L; Lubian E; Fedeli C; Visentin S; Polverino De Laureto P; Arrigoni G; Geffner-Smith A; Chen F; Simberg D; Morgese G; Benetti EM; Wu L; Moghimi SM; Mancin F; Papini E
ACS Nano; 2018 Jun; 12(6):5834-5847. PubMed ID: 29750504
[TBL] [Abstract][Full Text] [Related]
4. Validation of dot blot immunoassay for measurement of complement opsonization of nanoparticles.
Li Y; Monte A; Dylla L; Moghimi SM; Simberg D
J Immunol Methods; 2024 May; 528():113668. PubMed ID: 38574804
[TBL] [Abstract][Full Text] [Related]
5. The Nano-War Against Complement Proteins.
Wang Z; Brenner JS
AAPS J; 2021 Sep; 23(5):105. PubMed ID: 34505951
[TBL] [Abstract][Full Text] [Related]
6.
Wang G; Griffin JI; Inturi S; Brenneman B; Banda NK; Holers VM; Moghimi SM; Simberg D
Front Immunol; 2017; 8():151. PubMed ID: 28239384
[TBL] [Abstract][Full Text] [Related]
7. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.
Inturi S; Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
ACS Nano; 2015 Nov; 9(11):10758-68. PubMed ID: 26488074
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.
Vu VP; Gifford GB; Chen F; Benasutti H; Wang G; Groman EV; Scheinman R; Saba L; Moghimi SM; Simberg D
Nat Nanotechnol; 2019 Mar; 14(3):260-268. PubMed ID: 30643271
[TBL] [Abstract][Full Text] [Related]
9. Unravelling Heterogeneities in Complement and Antibody Opsonization of Individual Liposomes as a Function of Surface Architecture.
Münter R; Stavnsbjerg C; Christensen E; Thomsen ME; Stensballe A; Hansen AE; Parhamifar L; Kristensen K; Simonsen JB; Larsen JB; Andresen TL
Small; 2022 Apr; 18(14):e2106529. PubMed ID: 35187804
[TBL] [Abstract][Full Text] [Related]
10. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles.
Shan X; Yuan Y; Liu C; Tao X; Sheng Y; Xu F
Biomed Microdevices; 2009 Dec; 11(6):1187-94. PubMed ID: 19609680
[TBL] [Abstract][Full Text] [Related]
11. Complement-dependent uptake of nanoparticles by blood phagocytes: brief overview and perspective.
Li Y; Moein Moghimi S; Simberg D
Curr Opin Biotechnol; 2024 Feb; 85():103044. PubMed ID: 38091875
[TBL] [Abstract][Full Text] [Related]
12. Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles.
Capolla S; Colombo F; De Maso L; Mauro P; Bertoncin P; Kähne T; Engler A; Núñez L; Spretz R; Larsen G; Dal Bo M; Toffoli G; Macor P
J Nanobiotechnology; 2023 Oct; 21(1):376. PubMed ID: 37838659
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins.
Li Y; Jacques S; Gaikwad H; Wang G; Banda NK; Holers VM; Scheinman RI; Tomlinson S; Moghimi SM; Simberg D
Nat Nanotechnol; 2024 Feb; 19(2):246-254. PubMed ID: 37798566
[TBL] [Abstract][Full Text] [Related]
14. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D
Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582
[TBL] [Abstract][Full Text] [Related]
15. Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.
Gaikwad H; Li Y; Gifford G; Groman E; Banda NK; Saba L; Scheinman R; Wang G; Simberg D
Bioconjug Chem; 2020 Jul; 31(7):1844-1856. PubMed ID: 32598839
[TBL] [Abstract][Full Text] [Related]
16. Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins.
Bjornson AB; Magnafichi PI; Schreiber RD; Bjornson HS
J Exp Med; 1987 Mar; 165(3):777-98. PubMed ID: 3819646
[TBL] [Abstract][Full Text] [Related]
17. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo.
Chen F; Wang G; Griffin JI; Brenneman B; Banda NK; Holers VM; Backos DS; Wu L; Moghimi SM; Simberg D
Nat Nanotechnol; 2017 May; 12(4):387-393. PubMed ID: 27992410
[TBL] [Abstract][Full Text] [Related]
18. Engineering PEGylated Polyester Nanoparticles to Reduce Complement-Mediated Infusion Reaction.
Maisha N; Naik N; Okesola M; Coombs T; Zilberberg R; Pandala N; Lavik E
Bioconjug Chem; 2021 Oct; 32(10):2154-2166. PubMed ID: 34499487
[TBL] [Abstract][Full Text] [Related]
19. CH(50): a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction.
Meerasa A; Huang JG; Gu FX
Curr Drug Deliv; 2011 May; 8(3):290-8. PubMed ID: 21291380
[TBL] [Abstract][Full Text] [Related]
20. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
